Clinical trials: DNA Damage
Hyperbaric Oxygen, Genotoxicity
Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperbaric Oxygen Therapy in Patients Undergoing Radiotherapy for Neoplasia, on the Occurrence of DNA Damage
Hyperbaric Oxygen Therapy (HBOT) is a treatment involving the administration of oxygen at pressures higher than atmospheric pressure, with numerous potential indications such as radiation-induced tissue damage, chronic wounds…
- Conditions
- Hyperbaric Oxygen, Genotoxicity, Malignancy
- Trial name
- OXYBAR (NCT06999785)
- Testing
- Blood test
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Angers
Neoplasms, Lymphoma
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
Background: Cyclophosphamide (CP) is a drug approved by the Food and Drug Administration for the treatment of certain cancers. It works by causing DNA damage, resulting in cell death, including cancer cells.
- Trial name
- NCT01445522
- Testing
- ABT-888, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body…
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04266912
- Testing
- Avelumab, Berzosertib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
- Trial name
- NCT03248570
- Testing
- Pembrolizumab, Chemotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Liver Health
Dietary Intervention Study on Liver Health in Young Adults
This prospective randomized dietary intervention study investigates the effects of two dietary approaches on liver health in young adults over a 12-week period.
- Trial name
- NCT07786831
- Testing
- Mediterranean Diet Intervention, General Healthy Diet Intervention
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hochschule Campus Wien (University of Applied Sciences Campus Vienna)
HBOC Syndrome, DNA Damage
Nutritional Intervention and DNA Damage of Patients With HBOC
Breast and Ovarian Cancer Syndrome (HBOC) is characterized by mutations in tumor suppressor genes such as BRCA1 and BRCA2, which increase the carrier's risk of developing breast and ovarian cancer, especially before 40.
- Conditions
- HBOC Syndrome, DNA Damage, Nutrition Therapy
- Trial name
- NCT05306002
- Testing
- Antioxidant therapy
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Metabolic Syndrome, Insulin Resistance
Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage
Obesity usually brings with it disturbances in the body that increase the chances of developing serious diseases like diabetes and cancer.
- Conditions
- Metabolic Syndrome, Insulin Resistance, DNA Damage
- Trial name
- NCT02075307
- Testing
- Blueberry Powder
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Polycystic Ovary Syndrome, Chronic Periodontitis
Chronic Periodontitis and Polycystic Ovary Syndrome
Background: The aim of this study was to investigate the levels of malondialdehyde (MDA), total antioxidant status (TAS), 8-hydroxy-2´- deoxyguanosine (8-OHdG) in blood serum and saliva samples in female patients with chronic…
- Trial name
- NCT02954120
- Testing
- no intervention provided
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Skin Cancer, Heat Tolerance
Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals
The escalating environmental heat-stress associated with global warming is a societal challenge with large and potential harmful consequences for humans.
- Conditions
- Skin Cancer, Heat Tolerance, Heat-related Illness, Hyperthermia
- Trial name
- ICARUS (NCT07510061)
- Testing
- Controlled Heat and Ultraviolet Radiation Exposure Protocol
- Where
- 2 sites in Denmark, Greece
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Thessaly
COVID-19 Pneumonia
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients
Our aim in this study is to determine the positive effect of stem cell therapy applied on critically ill patients with coronavirus infection on DNA repair genes.
- Trial name
- REPAIR (NCT04898088)
- Testing
- Mesenchymal Stem Cells Transplantation
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi
Type 2 Diabetes, Cancer
Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)
The purpose of the study is to determine whether glycemic control (HbA1c) is linked to chromosomal damage in type 2 Diabetes patients
- Trial name
- MIKRODIAB (NCT02231736)
- Where
- Austria
- Volunteers
- 130 people
- Sponsor
- University of Vienna
Neoplasms
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
Background: The drug cisplatin treats certain cancers when given with other chemotherapy drugs. Researchers think combining cisplatin with 2 other drugs could block proteins that support cancer cell growth.
- Trial name
- NCT02723864
- Testing
- Veliparib + VX-970 + Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Metabolic Syndrome
Effects of Xanthohumol on Metabolic Syndrome Progression
A huge body of scientific evidence has suggested that xanthohumol (XAN) consumption, a polyphenol present in beer, has a positive effect on energy metabolism.
- Trial name
- XAN4Health (NCT03561116)
- Testing
- XAN
- Where
- Portugal
- Volunteers
- 76 people
- Sponsor
- Universidade do Porto
Head and Neck Squamous Cell Carcinoma
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
This biomarker study has been designed to assess the effects of different agents in both tumour tissue and peripheral samples to help inform the best combinations of DDR agents with immuno-oncology (IO) therapies.
- Trial name
- NCT03022409
- Testing
- Ceralasertib, Olaparib
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 21 people
- Sponsor
- AstraZeneca